Mark Wietecha Bio

Mark WeitechaMark is president and CEO of Children's Hospital Association, representing over 200 children’s hospitals and major pediatric programs with a mission to improve child health through innovation in care, education and research. CHA advances these aims by fostering national collaboration to improve pediatric health policy and practice better serving the unique health care needs of children.  This is accomplished through specialized CHA pediatric programming in public policy, advocacy, analytics, education, research and work improving the quality, safety and cost of care.

Prior to joining CHA in 2011, Mark was a management consultant with Kurt Salmon for 27 years, where he served as the firm’s executive chairman, responsible for over 2,000 professionals working across five continents in six languages. His professional work in both adult academic and pediatric medicine has been recognized as among the best in the country, and he has advised most of the U.S. News & World Report “Best” medical centers and children's hospitals. Mark has been named among the nation’s “Most Influential Consultants” by Consulting Magazine and as one of the "5 Healthcare Leaders to Know" by Becker's Review.  He is a regular presenter on the future of health care and cited in such media as the New York Times, Wall Street Journal and National Public Radio.

Mark currently serves on the boards of the Children’s Hospital Association, the Council of Teaching Hospitals and Health Systems of the AAMC, the Coalition to Protect America’s Health Care, OpenNotes, an organization advancing greater patient engagement in their own care, and Virtual PICU Systems, where he is past chairman of the board.  He is a former trustee and past chairman of the board of overseers of the UCLA Health System, a former director and past deputy chairman of the board of Management Consulting Group, a public London-listed company, and a former director and past chairman of the board of Kurt Salmon Associates. 

Mark's past training includes a Master of Science in pharmacology from the Ohio State University and a Master of Business Administration from Indiana University.  He is based in Washington, D.C.